Last $56.30 USD
Change Today -0.50 / -0.89%
Volume 3.9M
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1000 Mylan Boulevard

Canonsburg, PA 15317

United States

Phone: 724-514-1800

Fax:

rtnership with Biocon for the global marketplace. The product is a biosimilar to Roche's Herceptin, indicated for the treatment of HER2 overexpressing breast cancer. The company launched this product in India in 2014 and is marketing the product under the trade name Hertraz. Agila has a product portfolio of approximately 375 filings approved globally and marketed through a network covering 75 countries, including as of November 2013, approximately 320 filings pending approval globally. Agila’s product portfolio includes approximately 115 products, of which approximately 90 are new to the company’s overall product portfolio. As of December 2013, Agila had approximately 80 ANDAs approved by the FDA and 136 ANDAs pending FDA approval. Australia The company offers a portfolio of approximately 180 products in an aggregate of approximately 375 dosage strengths. Japan Beginning in 2013, the company established a long-term strategic collaboration with Pfizer Japan to develop, manufacture, distribute, and market generic drugs in Japan. Pfizer Japan’s responsibilities primarily consist of the commercialization of the combined generics portfolio and managing a combined marketing and sales effort. In Japan, together with the company’s partner, Pfizer Japan, it offers a portfolio of approximately 310 products in an aggregate of approximately 475 dosage strengths. New Zealand In New Zealand, the company is generics company in the country. Mylan New Zealand offers a portfolio of approximately 90 products in an aggregate of approximately 170 dosage strengths. Brazil The company began commercial operations in Brazil in 2013 through the acquisition of Agila. In this market, the company operates both a manufacturing platform and a commercial business focused on providing generic injectable products to the Brazilian hospital segment. Its sales into this market segment are made through distributors, as well as through tenders. SPECIALTY This segment’s specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). Mylan Specialty’s portfolio consists primarily of branded specialty injectable and nebulized products. A portion of Mylan Specialty’s revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the U.S. and internationally. Mylan Specialty has worldwide rights to the epinephrine auto-injector, which is supplied to Mylan Specialty by a wholly owned subsidiary of Pfizer Inc. Mylan Specialty’s formoterol fumarate inhalation solution includes Perforomist Inhalation Solution, a long-acting beta2-adrenergic agonist indicated for long-term, twice-daily administration in the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients, including those with chronic bronchitis and emphysema. Mylan Specialty has been issued various U.S. and international patents protecting Perforomist Inhalation Solution. In addition to EpiPen Auto-Injector and Perforomist Inhalation Solution, Mylan Specialty also markets ULTIVA, which is an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures and is generally administered by an infusion device. Customers and Marketing The company’s customers included McKesson Corporation and Cardinal Health, Inc. during 2013. Generics: In North America, the company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies, and GPOs. It also markets its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies, and government entities. These customers, called ‘indirect customers’, purchase its products primarily through its wholesale customers. In EMEA and the Rest of World, generic pharmaceuticals are sold to wholesalers, independent pharmacies, and in certain countries, directly to hospitals. The company’s API are sold primarily to generic FDF

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $56.30 USD -0.50

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $76.15 USD -0.33
Perrigo Co PLC $156.01 USD -1.52
UCB SA €70.01 EUR -0.43
WW Grainger Inc $231.68 USD -3.13
WESCO International Inc $66.87 USD -2.60
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 24.5x
Price/Sales 2.9x
Price/Book 6.3x
Price/Cash Flow 23.1x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.